AMGN - Amgen Outlook Is Bright Analyst Predict Obesity-Focused Drug Potential Will Drive Shareholder Value | Benzinga
Amgen Inc (NASDAQ:AMGN) reported first-quarter (Q1) earnings Thursday, touting adjusted EPS of $3.96, which beat the analyst consensus estimate of $3.87.
Here are highlights from the release and subsequent analyst call:
- Sales increased 22% Y/Y to $7.45 billion, which beat the analyst consensus estimate of $7.436 billion.
- Amgen sees full-year 2024 adjusted EPS of $19-$20.20 versus consensus of $19.48.
- The company is pulling the plug on AMG 786, an oral Phase 1 candidate for obesity, and remain focused on prioritizing differentiated medicines.
- Amgen CEO Robert Bradway said the company is “confident in MariTide’s differentiated profile and believe it will address important unmet medical needs.”
Also Read: Sandoz Settles Patent Dispute With Amgen Related To ...